Cell line · CVCL_0021
Papers213
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
21 to 40 of 213
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Chronic IFN-γ Exposure Induces Divergent Adaptive Programs in Glioblastoma Subtypes. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fenofibrate as an anti-cancer treatment: an in vitro study on glioblastoma cells at various oxygen levels and on normal astrocytes. | Cancer Cell Int | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NFYC upregulates KLF1 expression and activate LDHA to drive glycolysis and tumor growth in glioblastoma cells. | Front Cell Dev Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prognostic Stratification and Subtyping of Glioblastoma Using Transient Receptor Potential Channels. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual Targeting of DNA and EGFR by ZYH005 Induces DNA Damage and Mitotic Catastrophe in Glioblastoma. | MedComm (2020) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Vitro Anti-Glioblastoma Activity of a Novel Pt(IV)-Ganoderic Acid A Conjugate. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chemical Constituents of Taxodium mucronatum (Cupressaceae) and Some of Its Endophytic Fungi, and Their In Silico and In Vitro Evaluations as SARS-CoV-2 Inhibitors and as Cytotoxic Agents. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Imaging vascular characteristics and glycolytic metabolism of glioblastoma in a chick embryo model using 1H MRI and [18F]FDG-PET. | Mol Imaging Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylation. | Bioeng Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lipid Droplet-Localized Spindle Apparatus Coiled-Coil Protein 1 Regulates Lipid Droplet Distribution. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Paeonol Inhibits Cell Growth by Inducing Ferroptosis in Human Glioma Cells. | Pharmacol Res Perspect | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A prognostic gene signature derived from aging-related genes predicts survival, immune landscape and therapy response in glioma. | Mol Clin Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0021/papers?page=2